Pathogen Panel Testing
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Outpatient coverage policy for multiplex pathogen panel testing for infectious diseases, specifying which panels and target counts meet or do not meet BlueCross BlueShield of Tennessee coverage criteria.
CC2 and CC4 edited to add antigen panel testing; CC2 moved respiratory infection signs/symptoms into new Note 1; CC2 now allows panel testing of up to 5 respiratory pathogens for individuals displaying signs/symptoms; CC4 states testing of 6 or more respiratory pathogens does not meet coverage criteria.
New Note 1 lists signs and symptoms of respiratory tract infection, including age-specific signs in children and infants.
Added CPT code 87428 and laboratory codes 0556U, 0563U, 0564U (effective 7/1/2025).
Removed CPT codes 0240U, 0241U, 0369U, 0370U, 0373U, 0374U (deleted effective 7/1/2025).
Added CPT code 0531U (effective 4/1/2025).
Coverage Criteria for Multiplex Pathogen Panel Testing
Covered indications
Covered when ALL of the following are met for specified indications:
Outpatient setting only
See Note 1 for symptom list; outpatient only
Coverage determination depends on the member's benefit at time of request and applicable Medicare/Medicaid rules.
Not Medically Necessary / Not Covered
The following are explicitly not covered:
Not covered due to lack of sufficient published evidence for clinical benefit
Respiratory panel size-based coverage
Coverage for respiratory panel testing is defined by presence of clinical signs/symptoms and by panel size.
Documentation should demonstrate the individual is displaying signs and symptoms as defined in Note 1; outpatient only
Denial risk unless an exception elsewhere in policy applies
Molecular-based panel testing to screen for or diagnose wound infections, molecular detection-based panel testing of urine pathogens for the diagnosis of urinary tract infections, molecular detection-based panel testing of pathogens in blood, and molecular-based panel testing for general microorganism screening are not covered. These tests are considered to not meet coverage criteria due to insufficient published evidence demonstrating they are required and beneficial for the diagnosis and treatment of an individual’s illness.
Panel testing that includes 6 or more respiratory pathogen targets is explicitly excluded from coverage. The policy revision clarifies that antigen or multiplex PCR-based respiratory panels with >= 6 pathogens do not meet coverage criteria.
Molecular detection–based panel testing of urine pathogens for UTI diagnosis, molecular-based panel testing to diagnose wound infections, molecular detection–based panel testing of pathogens in blood, and broad general microorganism screening panels are considered not medically necessary / not covered because available published scientific literature does not confirm clinical benefit for diagnosis or treatment.
Antigen panel testing or multiplex PCR–based panel testing of 6 or more respiratory pathogens is stated in the policy to not meet coverage criteria. The revision emphasizes panel size as a determinant of coverage and identifies respiratory panels with ≥6 targets as a denial risk.
Coding and Test Code Lists
| 87154 | Culture, typing; identification of blood pathogen and resistance typing, multiplexed amplified probe technique, 6 or more targets. |
| 87428 | Infectious agent antigen detection by immunoassay; severe acute respiratory syndrome coronavirus and influenza A/B. |
| 87483 | Infectious agent detection by nucleic acid; central nervous system pathogen, 12-25 targets. |
| 87631 | Infectious agent detection by nucleic acid; respiratory virus, 3-5 targets. |
| 87632 | Infectious agent detection by nucleic acid; respiratory virus, 6-11 targets. |
| 87633 | Infectious agent detection by nucleic acid; respiratory virus, 12-25 targets. |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza A/B, multiplex amplified probe technique. |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza A/B, and RSV, multiplex amplified probe technique. |
| 0068U | Candida species panel, amplified probe technique, qualitative presence/absence (6 Candida species). |
| 0086U | Organism identification, blood culture using rRNA FISH, 6 or more organism targets with MIC-based susceptibility. |
Provider Actions, Documentation, and Authorization
Outpatient panel coverage requirement
Outpatient multiplex pathogen panel testing is subject to coverage criteria described in the policy. Providers must confirm the requested panel size and modality (antigen panel vs. multiplex PCR) against the covered limits and document clinical signs/symptoms when required. Prior authorization and coding changes may affect whether a request is approved.
- Confirm panel composition and testing modality prior to ordering.
- Verify member benefit and applicable Medicare/Medicaid rules for outpatient testing.
- Ensure documentation of clinical signs/symptoms when ordering respiratory or gastrointestinal panels.
Updated codes affect authorization
Coding updates made during recent revisions affect prior authorization and coverage determinations. Providers should verify that submitted CPT and proprietary laboratory codes are current and match the service performed; use updated codes for authorization requests to avoid delays or denials.
Denial triggers for unsupported panels
Requests for multiplex panels exceeding the policy's covered pathogen limits will be denied. Specifically, gastrointestinal panels of 12 or more pathogens and respiratory panels of 6 or more pathogens do not meet coverage criteria. Providers should order panels that fall within covered sizes or submit clinical justification and obtain prior authorization when an alternative approach is clinically necessary.
- Multiplex PCR-based GIP panels of 12 or more pathogens are NOT covered.
- Antigen or multiplex PCR respiratory panels of 6 or more pathogens are NOT covered.
- Order panels of 11 or fewer GIPs and 5 or fewer respiratory pathogens to meet coverage criteria.
Panel size exceeds covered limit
Panel testing requests that exceed covered limits will be denied as not meeting coverage criteria; verify panel size before submission and, if ordering larger panels for a specific clinical reason, provide detailed documentation and seek prior authorization.
- Antigen panel testing or multiplex PCR-based testing of 6 or more respiratory pathogens — will be denied.
- Multiplex PCR-based panel testing of 12 or more gastrointestinal pathogens — will be denied.
- Ensure clinical documentation supports testing and matches policy Note 1 signs/symptoms for respiratory infections when applicable.
Definitions and Clinical Signs
Multiplex amplified-probe and multiplex reverse-transcription methods allow detection of multiple pathogens from a single specimen with faster turnaround and may improve sensitivity or specificity compared with conventional culture or immunoassays. The policy focuses on outpatient use and aligns coverage with specific clinical indications; it also adds Note 1 defining required signs and symptoms when respiratory panel testing of up to 5 pathogens is considered covered.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.